SNO conference, San Francisco and Optune compliance - Hallo friendsTOP POLENNEWS, In the article you read this time with the title SNO conference, San Francisco and Optune compliance, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cultur, Article economic, Article health, Article news, Article politique, Article sport, We write this you can understand. Alright, good read.

Title : SNO conference, San Francisco and Optune compliance
link : SNO conference, San Francisco and Optune compliance

SNO conference, San Francisco and Optune compliance

Myself and a friend who also frequents this blog are at this year's SNO conference in San Francisco. I will be reporting on the conference very soon.

To get us started, here is a report from Novocure showing increased survival in the EF-14 trial for patients who achieved 90% or more compliance with Optune (that is to say, wore the Optune device for an average of 90% of the time each day).

Median survival (from randomization, which was 3.8 months after diagnosis), was 21.7 months with 70-80% compliance and 24.9 months with 90% or more compliance.  5-year survival rate in the 90% compliance group was 29.3%.

This dose-response effect is a powerful argument against those who would argue that the positive results in favor of Optune seen in this trial could be a result of a lack of a placebo control, or the result of increased supportive care in the Optune arm.

http://ift.tt/2ATsCSp

Thus Article SNO conference, San Francisco and Optune compliance

That's an article SNO conference, San Francisco and Optune compliance This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article SNO conference, San Francisco and Optune compliance with the link address https://polennews.blogspot.com/2017/11/sno-conference-san-francisco-and-optune.html

Tweet

Subscribe to receive free email updates: